专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012172277A1 SIMIAN ADENOVIRUS AND HYBRID ADENOVIRAL VECTORS 审中-公开
标题翻译： SIMIAN ADENOVIRUS和HYBRID ADENOVIRAL VECTORS
公开(公告)号：WO2012172277A1
公开(公告)日：2012-12-20
申请号：PCT/GB2012/000467
申请日：2012-05-25
申请人： ISIS INNOVATION LIMITED , DICKS, Matthew Douglas James , COTTINGHAM, Matthew Guy , HILL, Adrian Vivian Sinton , GILBERT, Sarah
发明人： DICKS, Matthew Douglas James , COTTINGHAM, Matthew Guy , HILL, Adrian Vivian Sinton , GILBERT, Sarah
IPC分类号： C12N15/86
CPC分类号： A61K48/00 , C12N5/0606 , C12N7/00 , C12N15/86 , C12N2710/10021 , C12N2710/10042 , C12N2710/10044 , C12N2800/204
摘要： The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors. In particular, the present invention provides an adenovirus vector comprising a capsid derived from chimpanzee adenovirus AdY25, wherein said capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest.
摘要翻译：本发明提供重组腺病毒载体，其免疫原性组合物及其在医学中的应用，以及用于产生重组腺病毒载体的方法。特别地，本发明提供了一种腺病毒载体，其包含源自黑猩猩腺病毒AdY25的衣壳，其中所述衣壳包裹包含感兴趣的外源核苷酸序列的核酸分子。

2. 发明申请

WO2009044165A3 MOLECULAR ADJUVANT 审中-公开
标题翻译：分子辅助剂
公开(公告)号：WO2009044165A3
公开(公告)日：2009-06-11
申请号：PCT/GB2008003366
申请日：2008-10-07
申请人： ISIS INNOVATIONS LTD , HILL ADRIAN VIVIAN SINTON , WYLLIE DAVID , LARSEN KAREN COLBJORN , SPENCER ALEXANDRA JANE , COTTINGHAM MATTHEW , GILBERT SARAH
发明人： HILL ADRIAN VIVIAN SINTON , WYLLIE DAVID , LARSEN KAREN COLBJORN , SPENCER ALEXANDRA JANE , COTTINGHAM MATTHEW , GILBERT SARAH
IPC分类号： A61K39/00 , A61K39/04 , A61K48/00
CPC分类号： A61K39/00 , A61K39/04 , A61K2039/53 , A61K2039/55516 , A61K2039/55522
摘要： This invention relates to the use of a molecular adjuvant to generate an immune response in a host. In particular, the molecular adjuvant may be a TLR signalling pathway component, a co-stimulatory molecule, an NKG2D ligand, IL- or IL-15.
摘要翻译：本发明涉及分子佐剂在宿主中产生免疫应答的用途。特别地，分子佐剂可以是TLR信号通路组分，共刺激分子，NKG2D配体，IL或IL-15。

3. 发明申请

WO2011098837A1 METHOD FOR THE PRODUCTION OF STABLE LIVE VACCINE FORMULATIONS 审中-公开
标题翻译：生产稳定的活体疫苗制剂的方法
公开(公告)号：WO2011098837A1
公开(公告)日：2011-08-18
申请号：PCT/GB2011/050277
申请日：2011-02-14
申请人： ISIS INNOVATION LIMITED , NOVA LABORATORIES LTD , ALCOCK, Robert , DE COSTA, Samodh , COTTINGHAM, Matthew , ROLLIER, Christine , HILL, Adrian , BREGU, Migena , WYLLIE, David , GILBERT, Sarah , SPENCER, Alexandra
发明人： ALCOCK, Robert , DE COSTA, Samodh , COTTINGHAM, Matthew , ROLLIER, Christine , HILL, Adrian , BREGU, Migena , WYLLIE, David , GILBERT, Sarah , SPENCER, Alexandra
IPC分类号： A61K9/16 , A61K39/12 , C12N7/02
CPC分类号： A61K39/12 , A61K39/015 , A61K2039/5254 , A61K2039/5256 , C12N7/00 , C12N2710/10343 , C12N2710/10351 , C12N2710/24143 , C12N2710/24151 , Y02A50/412
摘要： The present application relates to a method of stabilising a virus selected from modified vaccinia Ankara (MVA) virus or E1/E3-deleted human adenovirus serotype 5 (AdHu5), wherein said virus retains activity after storage, the method comprising: (a) forming a liquid mixture of the virus with a glass-forming excipient which comprises trehalose and sucrose; (b) applying said liquid mixture to a support; and (c) drying said liquid mixture at a temperature that does not exceed 35°C and does not fall below 1°C to form a glass containing the virus, wherein said virus retains activity after storage in the glass at 45°C for at least 4 months, and wherein said virus expresses an antigen selected from a malarial antigen, an influenza antigen, a tuberculosis antigen and/or an HIV antigen.
摘要翻译：本申请涉及一种稳定选自修饰牛痘安卡拉（MVA）病毒或E1 / E3缺失的人腺病毒血清型5（AdHu5）的病毒的方法，其中所述病毒在储存后保留活性，所述方法包括：（a）形成病毒与包含海藻糖和蔗糖的玻璃形成赋形剂的液体混合物; （b）将所述液体混合物施加到载体上; 和（c）在不超过35℃并且不低于1℃的温度下干燥所述液体混合物以形成含有病毒的玻璃，其中所述病毒在45℃下保存在玻璃中后保持活性，以在至少4个月，并且其中所述病毒表达选自疟疾抗原，流感抗原，结核抗原和/或HIV抗原的抗原。

4. 发明申请

WO2009044165A2 MOLECULAR ADJUVANT 审中-公开
标题翻译：分子辅助剂
公开(公告)号：WO2009044165A2
公开(公告)日：2009-04-09
申请号：PCT/GB2008/003366
申请日：2008-10-07
申请人： ISIS INNOVATIONS LIMITED , HILL, Adrian, Vivian, Sinton , WYLLIE, David , LARSEN, Karen, Colbjorn , SPENCER, Alexandra, Jane , COTTINGHAM, Matthew , GILBERT, Sarah
发明人： HILL, Adrian, Vivian, Sinton , WYLLIE, David , LARSEN, Karen, Colbjorn , SPENCER, Alexandra, Jane , COTTINGHAM, Matthew , GILBERT, Sarah
IPC分类号： A61K39/00 , A61K39/04 , A61K48/00
CPC分类号： A61K39/00 , A61K39/04 , A61K2039/53 , A61K2039/55516 , A61K2039/55522 , Y02A50/386 , Y02A50/41 , Y02A50/412
摘要： This invention relates to the use of a molecular adjuvant to generate an improved immune response in a host. In particular, the molecular adjuvant may be a TLR signalling pathway component, a co-stimulatory molecule, an NKG2D ligand, IL-7 or IL-15.
摘要翻译：本发明涉及分子佐剂在宿主中产生改善的免疫应答的用途。特别地，分子佐剂可以是TLR信号通路组分，共刺激分子，NKG2D配体，IL-7或IL-15。

5. 发明申请

WO2012172277A4 SIMIAN ADENOVIRUS AND HYBRID ADENOVIRAL VECTORS 审中-公开
标题翻译： SIMIAN ADENOVIRUS和HYBRID ADENOVIRAL VECTORS
公开(公告)号：WO2012172277A4
公开(公告)日：2013-04-04
申请号：PCT/GB2012000467
申请日：2012-05-25
申请人： ISIS INNOVATION , DICKS MATTHEW DOUGLAS JAMES , COTTINGHAM MATTHEW GUY , HILL ADRIAN VIVIAN SINTON , GILBERT SARAH
发明人： DICKS MATTHEW DOUGLAS JAMES , COTTINGHAM MATTHEW GUY , HILL ADRIAN VIVIAN SINTON , GILBERT SARAH
IPC分类号： C12N15/86
CPC分类号： A61K48/00 , C12N5/0606 , C12N7/00 , C12N15/86 , C12N2710/10021 , C12N2710/10042 , C12N2710/10044 , C12N2800/204
摘要： The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors. In particular, the present invention provides an adenovirus vector comprising a capsid derived from chimpanzee adenovirus AdY25, wherein said capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest.
摘要翻译：本发明提供重组腺病毒载体，其免疫原性组合物及其在医学中的应用，以及用于产生重组腺病毒载体的方法。特别地，本发明提供了一种腺病毒载体，其包含源自黑猩猩腺病毒AdY25的衣壳，其中所述衣壳包裹包含感兴趣的外源核苷酸序列的核酸分子。

6. 发明申请

WO2011110864A1 PROMOTER SEQUENCE FOR DNA AND VIRAL VECTORS 审中-公开
标题翻译： DNA和病毒载体的推测序列
公开(公告)号：WO2011110864A1
公开(公告)日：2011-09-15
申请号：PCT/GB2011/050485
申请日：2011-03-11
申请人： ISIS INNOVATION LIMITED , WYLLIE, David Hamilton , COTTINGHAM, Matthew Guy
发明人： WYLLIE, David Hamilton , COTTINGHAM, Matthew Guy
IPC分类号： C12N15/861
CPC分类号： C12N15/86 , C12N2710/10343 , C12N2830/006 , C12N2830/15 , C12N2830/20 , C12N2830/60 , C12N2830/80
摘要： There is provided a viral vector comprising a first promoter sequence, wherein the first promoter sequence comprises: (a) a nucleic acid sequence having at least 70% sequence identity to the nucleic acid sequence of SEQ ID NO: 1;or (b) at least two fragments of (a), wherein each fragment comprises at least consecutive nucleotides of (a); or (c) a fragment of (a), wherein said fragment comprises at least 20 consecutive nucleotides of (a). Also provided are corresponding uses of the viral vector in medicine.
摘要翻译：提供包含第一启动子序列的病毒载体，其中第一启动子序列包含：（a）与SEQ ID NO：1的核酸序列具有至少70％序列同一性的核酸序列;或（b）（a）的至少两个片段，其中每个片段至少包含（a）的连续核苷酸; 或（c）（a）的片段，其中所述片段包含（a）的至少20个连续核苷酸。还提供病毒载体在药物中的相应用途。

7. 发明申请

WO2011045612A1 MYCOBACTERIAL VACCINES 审中-公开
公开(公告)号：WO2011045612A1
公开(公告)日：2011-04-21
申请号：PCT/GB2010/051741
申请日：2010-10-15
申请人： ISIS INNOVATION LIMITED , IMAXIO SA , SPENCER, Alexandra, Jane , COTTINGHAM, Matthew, Guy , HILL, Adrian, Vivian, Sinton , HILL, Fergal
发明人： SPENCER, Alexandra, Jane , COTTINGHAM, Matthew, Guy , HILL, Adrian, Vivian, Sinton , HILL, Fergal
IPC分类号： C07K14/435 , C12N15/62
CPC分类号： C07K14/435 , A61K39/04 , C07K16/1289 , C12N15/62
摘要： There is provided a fusion protein or a polynucleotide sequence encoding said fusion protein that comprises first and second domains, wherein the first domain of the fusion protein comprises an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 1, or a fragment thereof comprising at least 20 consecutive amino acids thereof; and wherein the second domain of the fusion protein comprises a mycobacterial antigen or an antigenic fragment thereof. Also provided are corresponding therapeutic uses thereof for the protection of primates against mycobacterial infections.
摘要翻译：提供了编码包含第一和第二结构域的融合蛋白的融合蛋白或多核苷酸序列，其中融合蛋白的第一结构域包含与SEQ ID NO的氨基酸序列具有至少70％序列同一性的氨基酸序列：1或其包含其至少20个连续氨基酸的片段; 并且其中所述融合蛋白的第二结构域包含分枝杆菌抗原或其抗原性片段。还提供了用于保护灵长类动物免受分枝杆菌感染的相应治疗用途。

8. 发明申请

WO2002042778A3 FOR AMYLOID FORMATION INHIBITORS 审中-公开
公开(公告)号：WO2002042778A3
公开(公告)日：2002-05-30
申请号：PCT/GB2001/005189
申请日：2001-11-23
申请人： SYNAPTICA LIMITED , VAUX, David, John, Talbutt , COTTINGHAM, Matthew, Guy , VOSKUIL, Jan, Louis, Albert
发明人： VAUX, David, John, Talbutt , COTTINGHAM, Matthew, Guy , VOSKUIL, Jan, Louis, Albert
IPC分类号： G01N33/68
摘要： There are disclosed screening assays stemming from the finding that a fragment of acetylcholinesterase (SEQ.ID no. 1; Synaptica Peptide) forms amyloid-type fibrils and has a surfactant effect dependent on the peptide concentration and the pH of the solution. Compounds capable of preventing lowering of surface tension by Synaptica Peptide are of particular interest in relation to neurodegenerative disorders, which have been linked to non-enzymic function of acetylcholinesterase in the brain, especially Alzheimer's Disease, Parkinson's Disease and Motor Neuron Disease.

9. 发明申请

WO0242778A2 SCREENING ASSAYS 审中-公开
标题翻译：筛选测试
公开(公告)号：WO0242778A2
公开(公告)日：2002-05-30
申请号：PCT/GB0105189
申请日：2001-11-23
申请人： SYNAPTICA LTD , VAUX DAVID JOHN TALBUTT , COTTINGHAM MATTHEW GUY , VOSKUIL JAN LOUIS ALBERT
发明人： VAUX DAVID JOHN TALBUTT , COTTINGHAM MATTHEW GUY , VOSKUIL JAN LOUIS ALBERT
IPC分类号： G01N33/68 , G01N33/94
CPC分类号： G01N33/944 , G01N33/6896 , G01N2333/4709 , G01N2500/00
摘要： There are disclosed screening assays stemming from the finding that a fragment of acetylcholinesterase (SEQ.ID no. 1; Synaptica Peptide) forms amyloid-type fibrils and has a surfactant effect dependent on the peptide concentration and the pH of the solution. Compounds capable of preventing lowering of surface tension by Synaptica Peptide are of particular interest in relation to neurodegenerative disorders, which have been linked to non-enzymic function of acetylcholinesterase in the brain, especially Alzheimer's Disease, Parkinson's Disease and Motor Neuron Disease.
摘要翻译：公开了由乙酰胆碱酯酶（SEQ.ID No.1; Synaptica Peptide）的片段形成淀粉样蛋白型原纤维并且具有取决于肽浓度和溶液pH的表面活性效应的发现的筛选试验。能够防止Synaptica肽降低表面张力的化合物对于与脑中的乙酰胆碱酯酶的非酶功能，特别是阿尔茨海默病，帕金森病和运动神经元疾病有关的神经退行性疾病特别有兴趣。

10. 发明申请

WO2011128704A1 POXVIRUS EXPRESSION SYSTEM 审中-公开
标题翻译： POXVIRUS表达系统
公开(公告)号：WO2011128704A1
公开(公告)日：2011-10-20
申请号：PCT/GB2011/050757
申请日：2011-04-15
申请人： ISIS INNOVATION LIMITED , COTTINGHAM, Matthew Guy
发明人： COTTINGHAM, Matthew Guy
IPC分类号： C12N15/863 , A61K39/00
CPC分类号： C12N15/86 , A61K39/00 , A61K48/00 , A61K2039/5256 , C12N7/00 , C12N15/66 , C12N15/8636 , C12N2710/24143 , C12N2800/204 , C12N2800/50 , C12N2830/34 , Y02A50/412
摘要： There is provided a method for inserting a nucleic acid sequence that encodes a foreign peptide into a poxvirus genome, said method comprising: identifying in the poxvirus genome a poxvirus open reading frame wherein said open reading frame is characterised by an initial ATG start codon and wherein expression of said open reading frame is driven by an operably-linked poxvirus promoter located upstream of the open reading frame and wherein expression of said open reading frame provides a peptide that is non-essential to viability of the poxvirus; and inserting the nucleic acid sequence that encodes the foreign peptide at a position downstream of the poxvirus promoter; wherein following said insertion, (i) the nucleic acid that encodes the foreign peptide is operably-linked to the poxvirus promoter and expression of said nucleic acid is driven by said poxvirus promoter; and (ii) translation of the foreign peptide is initiated at an ATG start codon located at the same position as the ATG start codon of the poxvirus open reading frame. Also provided are a poxvirus vector and corresponding uses of the poxvirus vector in medicine.
摘要翻译：提供了将编码外源肽的核酸序列插入痘病毒基因组的方法，所述方法包括：在痘病毒基因组中鉴定痘病毒开放阅读框，其中所述开放阅读框的特征在于初始的ATG起始密码子，其中所述开放阅读框的表达由位于开放阅读框上游的可操作连接的痘病毒启动子驱动，并且其中所述开放阅读框的表达提供了对痘病毒的活力非必需的肽; 并将编码外源肽的核酸序列插入到痘病毒启动子下游的位置; 其中在所述插入之后，（i）编码外来肽的核酸与痘病毒启动子可操作地连接，并且所述核酸的表达由所述痘病毒启动子驱动; 和（ii）外源肽的翻译起始于位于与痘病毒开放阅读框的ATG起始密码相同位置的ATG起始密码子。还提供了痘病毒载体和痘病毒载体在药物中的相应用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式